Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in salivary ionocytes | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 15370
Sealed predictions
- DGKI in dopamine neurons, braak+0.80 (p 0.010) → -0.11 (p 0.787)receipt 15377
Swarm cases
receipt 15377: DGKI in dopamine neurons, braak
- power
- full sample +0.31 (p 0.218, n 18), 95% CI -0.19 to +0.68. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.29 (p 0.235, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.23 (p 0.365, n 18). could be the mix.
- skeptic
- leave-one-out range +0.23 to +0.47, sign flips 0; without severely affected donors +0.31 (p 0.218, n 18). fragile.
- cell type
- strongest in OPCs: +0.66 (p 0.0026, n 18) vs +0.31 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DGKI in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up DGKI · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.18 p 0.534 (needs p < 1.5e-4)
Receipts
loading the receipts